BFRI
Biofrontera Inc.
$0.9300
-0.53%
$11.3M
No data for this timeframe.
Vol
Market Cap$11.3M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders2 funds
Inst. Value$65.0K
Inst. Activity0 buys / 1 sells
SEC Reports3
Press Releases1
Recent Activity
Sep 28, 2026
fda_pdufa
PDUFA: BFRI — Ameluz in superficial basal cell carcinoma (sBCC) — 2026-09-28
FDA target action date 2026-09-28 for BFRI (Biofrontera Inc.). Drug: Ameluz. Indication: superficial
May 14, 2026
SEC
Biofrontera reported Q1 2026 revenue of $10.1M (+17% YoY), gross margins expanding to ~80% from ~62%, and near-zero cash
PRESS-RELEASE — Impact 7/10
May 8, 2026
SEC
Biofrontera Inc. announced it will report Q1 2026 financial results on May 14, 2026, after market close, followed by a c
PRESS-RELEASE — Impact 2/10
Mar 19, 2026
Press
Biofrontera Inc. reported strong fourth-quarter and full-year 2025 results, with record Q4 revenue of $17.1 million (up
Impact 8/10
Mar 5, 2026
Insider
Luebbert Hermann sold 137,500 shares
CEO & Chairman @ $0.00 ($0.00)
Mar 5, 2026
Insider
Leffler Eugene Frederick sold 87,500 shares
Chief Financial Officer @ $0.00 ($0.00)
Mar 5, 2026
Insider
Leffler Eugene Frederick sold 87,500 shares
Chief Financial Officer @ $0.00 ($0.00)
Feb 26, 2026
SEC
Biofrontera Inc. announced a favorable Final Written Decision from the U.S. Patent Trial and Appeal Board, which found a
8-K — Impact 8/10
Price Targets
$5.88
+567.6% upside
Strong Buy
Current $0.8800
Low $2.75
Median $5.88
High $9.00
2 analysts
$2.75
$9.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | Benchmark | DOWNGRADE | Buy → Speculative Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.04 ▲ +63.6% | $-0.04 — $-0.04 | 93% YoY | 1 |
| Next Q | $-0.11 | $-0.11 — $-0.11 | 81% YoY | 1 |
| Current FY | $-0.16 ▼ -166.7% | $-0.16 — $-0.16 | 87% YoY | 1 |
| Next FY | $0.32 | $0.32 — $0.32 | 300% YoY | 1 |
Latest Reports
BULLISH
PRESS-RELEASE
7/10
Biofrontera reported Q1 2026 revenue of $10.1M (+17% YoY), gross margins expanding to ~80% from ~62%, and near-zero cash
May 14, 2026
NEUTRAL
PRESS-RELEASE
2/10
Biofrontera Inc. announced it will report Q1 2026 financial results on May 14, 2026, after market close, followed by a c
May 8, 2026
BULLISH
Press
8/10
Biofrontera Inc. reported strong fourth-quarter and full-year 2025 results, with record Q4 revenue of $17.1 million (up
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $65.0K | NEW |
| BANK OF AMERICA CORP | $47.00 | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 5, 2026 | Luebbert Hermann | M | $0.00 |
| Mar 5, 2026 | Leffler Eugene | M | $0.00 |
| Mar 5, 2026 | Leffler Eugene | M | $0.00 |
| Mar 5, 2026 | Luebbert Hermann | M | $0.00 |
| Mar 4, 2026 | Luebbert Hermann | A | $0.00 |
2 institutional holders with $65.0K total value (114,033 shares) as of 2025-Q4. Top holders: VANGUARD, BANK. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 113,951 | $65.0K | 99.9% | NEW |
| 2 | BANK OF AMERICA CORP /DE/ | 82 | $47.00 | 0.1% | ADD +44.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 18,700 | 0 | -100.0% | $0.00 | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 113,951 | — | $112.2K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 18,700 | — | $18.4K | 2025-Q3 |
| UBS Group AG | DOUBLED | 31 | 1,001 | +3129.0% | $713.00 | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 43 | 62 | +44.2% | $44.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 28,224 | — | $22.6K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 14,073 | 31 | -99.8% | $25.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 3,099 | 14,073 | +354.1% | $15.3K | 2024-Q4 |
7 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Luebbert Hermann | CEO & Chairman | M | 137,500 | $0.00 | $0.00 |
| Mar 5, 2026 | Leffler Eugene Frederick | Chief Financial Officer | M | 87,500 | $0.00 | $0.00 |
| Mar 5, 2026 | Leffler Eugene Frederick | Chief Financial Officer | M | 87,500 | $0.00 | $0.00 |
| Mar 5, 2026 | Luebbert Hermann | CEO & Chairman | M | 137,500 | $0.00 | $0.00 |
| Mar 4, 2026 | Luebbert Hermann | CEO & Chairman | A | 125,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Luebbert Hermann | CEO & Chairman | A | 125,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Leffler Eugene Frederick | Chief Financial Officer | A | 62,500 | $0.00 | $0.00 |
| Mar 4, 2026 | Leffler Eugene Frederick | Chief Financial Officer | A | 62,500 | $0.00 | $0.00 |
| Mar 4, 2026 | Weber Kevin Daniel | Director | A | 20,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Lanckriet Heikki | Director | A | 20,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Hoffman Beth J. | Director | A | 20,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Jones George Patrick | Chief Commercial Officer | A | 50,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Jones George Patrick | Chief Commercial Officer | A | 50,000 | $0.00 | $0.00 |
| Mar 4, 2026 | BORER JOHN J III | Director | A | 20,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
BULLISH
PRESS-RELEASE
7/10
Biofrontera reported Q1 2026 revenue of $10.1M (+17% YoY), gross margins expanding to ~80% from ~62%
May 14, 2026
NEUTRAL
PRESS-RELEASE
2/10
Biofrontera Inc. announced it will report Q1 2026 financial results on May 14, 2026, after market cl
May 8, 2026
BULLISH
8-K
8/10
Biofrontera Inc. announced a favorable Final Written Decision from the U.S. Patent Trial and Appeal
Feb 26, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.88 mean target
+567.6% upside
Strong Buy (3.00)
$2.75 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $0.8800 |
| Target Low | $2.75 |
| Target Mean | $5.88 |
| Target Median | $5.88 |
| Target High | $9.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.04 | $-0.04 | $-0.04 | 92.9% | +63.6% | 1↑ 0↓ | $0.0B | 5.2% | 1 |
| Next Q 2026-09-30 |
$-0.11 | $-0.11 | $-0.11 | 80.7% | +0.0% | 1↑ 0↓ | $0.0B | 28.8% | 1 |
| Current FY 2026-12-31 |
$-0.16 | $-0.16 | $-0.16 | 86.6% | -166.7% | 0↑ 1↓ | $0.0B | 9.4% | 1 |
| Next FY 2027-12-31 |
$0.32 | $0.32 | $0.32 | 300.0% | — | — | $0.1B | 15.4% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.040 | |
| 7d ago | $-0.110 | +0.070 |
| 30d ago | $-0.110 | +0.070 |
| 60d ago | $-0.120 | +0.080 |
| 90d ago | $-0.120 | +0.080 |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | Benchmark | DOWNGRADE | Buy | Speculative Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Sep 28, 2026
fda_pdufa
PDUFA: BFRI — Ameluz in superficial basal cell carcinoma (sBCC) — 2026-09-28
FDA target action date 2026-09-28 for BFRI (Biofrontera Inc.). Drug: Ameluz. Indication: superficial basal cell carcinoma (sBCC). FDA accepted sNDA fi
May 21, 2026
routine
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
<p align="justify">WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceut
May 14, 2026
earnings
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
<p align="justify">Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company special
May 14, 2026
earnings_calendar
BFRI Q1 2026 Earnings Scheduled — 2026-05-14
May 13, 2026
earnings_calendar
BFRI Q1 2026 Earnings Scheduled — 2026-05-13
May 8, 2026
earnings
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
<p align="justify"><b>WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”)</b>, a biopha
Mar 19, 2026
earnings
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
<p align="center"><b>Conference call will be held today, Thursday, March 19 at 10:00 am ET</b></p>
Mar 19, 2026
earnings_calendar
BFRI Q4 2025 Earnings After Market Close — 2026-03-19
Mar 9, 2026
earnings
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
<p align="justify"><b>WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”)</b>, a biop
Mar 9, 2026
other
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
<p align="justify"><b>• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz</b><sup><b>®</b></sup><b> PDT versus v